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Introduction
- Hepatobiliary neoplasia is uncommon in dogs. Frequently are malignant and secondary tumors from spleen, gastrointestinal tract and pancreas that 
metastasize to the liver. The majority of dogs diagnosed are older than 10 years of age and show nonspecific clinical signs. 
- Hepatocellular carcinoma accounts for > 50% of primary liver tumors. Early detection is difficult and only enables a complete surgical resection of 
massive morphology appearance without metastases.  
Objectives
- Make a current bibliographic review of canine liver tumors.
- Research on current and future therapies for management of unresectable human hepatocellular carcinoma and discuss the advantages and 
contraindications to asses which of them could be good therapeutic strategy for this neoplasia in dogs. 
Semiology and physical examination  
§ Approximately 25% of affected dogs show no clinical 
signs. 
§ Clinical signs are nonspecific (normally associated 
with gastrointestinal tract).
§ Hepatomegaly or cranial abdominal mass is the most 
common physical examination abnormality.
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Treatment  approach of canine hepatocellular carcinoma (HCC) 
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Hepatocellular carcinoma in a dog. (Balkman 2009 ) 
Election. Rare recurrences (0-13%).
Median overall survival (OS) > 4 years.
Not recommend for metastatic tumour
May not be possible if HCC involves the cava vein.
• Indicated if surgical resection is not possible.
It has been reported with moderate success in the
palliation of four dogs with HCC.
• Nivolumab showed antitumor activity and tolerated 
safety in advanced human HCC.
Incidence of primary malignant liver tumors. (Pastor and Planellas 2013) 
Conclusions
• HCC may progress silently in dogs with sufficient liver function and escape early diagnosis due to vague complaints and non-specific symptom.
• Prognosis and therapy options depends to the combination of histological and morphological pattern.
• Liver lobectomy is the gold standard for dogs with massive HCC but tumours with suck risk factors should be poor prognostic.
• RFA seems to be a good future curative strategy for canine HCC.
• Multikinase inhibitors and anti-PD1 are offering hopeful results as future individualized strategy for HCC treatment.
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• Abdominal RX: often reveal a cranial abdominal mass with caudal and lateral
displacement of the stomach.
• Abdominal US: determine morphology, size and location of tumors and its
relationship with adjacent structures (cava vein, gallbladder). Metastases and tumor
vascularization (Doppler).
• CT / RMI: diagnosis and staging liver tumors. MRI has more sensitivity (100%) and
specificity (90%) for differentiation of malignant and benign masses.
• Cytology and /or histology  àDefinitive diagnosis.
• A correct diagnosis is obtained in > 60% of hepatic aspirates and 90% of biopsies.
Primary malignant hepatic tumors
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• Toceranib showed a clinical benefit. Are required
more studies to validate which usefulness.
Futures therapeutic strategies (?)
• Complete responses in > 90% of human HCC <0.3 cm.
• Combination with CE ( size, recurrence).
Radiofrequency ablation 
Immune- checkpoint
inhibitors (anti PD-1)
